Skip to main content
. 2021 Mar 3;49:101204. doi: 10.1016/j.molmet.2021.101204

Figure 7.

Figure 7

Mogat1 ASO treatment improves glucose tolerance in whole-body Mogat1 null mice on an HFD. Male wild-type (WT) and littermate Mogat1 whole-body knockout (MOKO) mice were fed an HFD starting at 8 weeks of age. After 16 weeks of diet, mice were injected (intraperitoneal) twice weekly with ASOs targeted against Mogat1 or scramble control (25 mg/kg) for 3 weeks. Mice were fasted for 4 h prior to sacrifice and tissue collection. A–C: Mogat1 ASO treatment improves glucose tolerance and AUC independently of Mogat1 expression and lowers plasma insulin in WT mice. D: Mogat1 gene expression was reduced by ASO treatment and nearly absent in MOKO livers. E: Gene expression markers of interferon type-1 alpha/beta signaling are increased in Mogat1 ASO treated MOKO mice on HFD. Data are expressed as means ± S.E.M, and two-way ANOVA with Sidak's or Tukey's multiple comparison test were performed where appropriate #p < 0.05 from scramble ASO †p < 0.05 from WT controls; n = 5–7.